Prothena Corporation PLC (OQ:PRTA)

Business Focus: Bio Therapeutic Drugs

Apr 15, 2024 04:05 pm ET

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia & Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies.

Mar 05, 2024 04:05 pm ET

Prothena to Participate in Upcoming Healthcare Conferences

Mar 04, 2024 04:05 pm ET

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company’s vision and overall growth strategy.

Feb 21, 2024 04:05 pm ET

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board’s regular succession planning.

Feb 15, 2024 04:05 pm ET

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2023. In addition, the Company provided 2024 financial guidance and business highlights.

Feb 08, 2024 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

Jan 08, 2024 08:30 am ET

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Nov 02, 2023 04:05 pm ET

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 26, 2023 04:05 pm ET

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2023 financial results on Thursday, November 2, 2023 after the close of the U.S. financial markets.

Aug 31, 2023 04:05 pm ET

Prothena to Participate in Upcoming Healthcare Conferences

Aug 03, 2023 04:05 pm ET

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 27, 2023 04:05 pm ET

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2023 financial results on Thursday, August 3, 2023 after the close of the U.S. financial markets.

Jul 17, 2023 08:35 am ET

Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today shared data on three investigational product programs for the treatment and prevention of Alzheimer’s disease, PRX005, PRX012 and PRX123, at the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.

Jul 11, 2023 04:05 pm ET

Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually. Participation includes three posters highlighting the company’s next generation therapies for Alzheimer’s disease and a Prothena sponsored symposium.

Jul 10, 2023 04:10 pm ET

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005 and will pay Prothena $55 million. PRX005, which is designed to be a best-in-class anti-tau antibody, specifically targets an area within the microtubule binding region (MTBR) of tau for the potential treatment of Alzheimer’

Jun 27, 2023 04:05 pm ET

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication of the Phase 3 VITAL clinical trial in Blood, a journal of the American Society of Hematology (ASH). The published data demonstrate that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit of 74 percent was observed for those treated with birtamimab plus standard of care (SOC) versus 49 percent in patients on placeb

Jun 02, 2023 04:05 pm ET

Prothena to Participate in Jefferies 2023 Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 1:00 pm ET.

May 16, 2023 04:05 pm ET

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Billy Dunn, M.D., to its Board of Directors. Dr. Dunn is the founding and former Director of the Office of Neuroscience, Center for Drug Evaluation and Research (CDER), at the U.S. Food and Drug Administration (FDA).

May 04, 2023 04:05 pm ET

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023 04:05 pm ET

Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 after the close of the U.S. financial markets.

Apr 24, 2023 04:05 pm ET

Prothena to Participate in 2023 Bank of America Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on Tuesday, May 9, 2023 at 9:20 AM PT.

Apr 13, 2023 08:00 am ET

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthcare companies and compliance framework to match patient populations to this Prothena clinical trial for PRX012, which has been granted Fast Tra

Mar 31, 2023 09:20 am ET

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden.

Mar 21, 2023 04:05 pm ET

Prothena to Participate in Stifel 2023 Virtual CNS Days

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday March 28, 2023 at 10:30 AM ET.

Mar 14, 2023 04:05 pm ET

Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena's leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

Feb 23, 2023 04:05 pm ET

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2022. In addition, the Company provided 2023 financial guidance and business highlights.

Feb 16, 2023 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

Feb 03, 2023 04:05 pm ET

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 85,000 ordinary shares of the Company. The option has an exercise price per share equal to $53.67, which was the closing trading price on February 1, 2023, the date of the grant. The option will vest over four years, with

Jan 31, 2023 04:05 pm ET

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. PRX005 is one of three programs in the global neuro

Dec 14, 2022 10:38 pm ET

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 487,500 of its ordinary shares.

Dec 13, 2022 04:12 pm ET

Prothena Announces Proposed Public Offering of Ordinary Shares

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold.

Dec 12, 2022 11:30 am ET

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit was observed in those treated with birtamimab at 9 months. The survival benefit of birtamimab in VITAL remained consistent across all key baseline variables in patients with Mayo Stage IV AL amyloidosis. The data were present

Nov 21, 2022 04:05 pm ET

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $40 million milestone payment from Novo Nordisk related to the continued advancement of NNC6019 (formerly PRX004) in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy. There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs.

Nov 03, 2022 04:05 pm ET

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 03, 2022 09:05 am ET

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the American Society of Hematology Conference 2022 (ASH). The meeting will be held December 10-13, 2022 in New Orleans, LA.

Oct 27, 2022 04:05 pm ET

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

Sep 28, 2022 08:39 am ET

Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies?

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABOS, PRTA, AVXL, OCGN, and OSUR.

Sep 01, 2022 04:20 pm ET

Prothena to Participate in Upcoming Healthcare Conferences

Sep 01, 2022 04:05 pm ET

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Aug 08, 2022 04:05 pm ET

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 02, 2022 04:05 pm ET

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 01, 2022 04:05 pm ET

Prothena to Report Second Quarter 2022 Financial Results on August 8th

Jul 01, 2022 04:16 pm ET

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 02, 2022 04:05 pm ET

Prothena to Participate in Jefferies Healthcare Conference

May 05, 2022 04:05 pm ET

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

Apr 28, 2022 04:05 pm ET

Prothena to Report First Quarter 2022 Financial Results on May 5th

Apr 26, 2022 08:30 am ET

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Mar 28, 2022 08:30 am ET

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has...

Mar 21, 2022 04:05 pm ET

Prothena to Participate in Stifel 2022 Virtual CNS Days

Mar 16, 2022 05:30 am ET

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

Feb 17, 2022 04:05 pm ET

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 10, 2022 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022

Nov 29, 2021 04:05 pm ET

Prothena to Participate in JMP Securities Hematology and Oncology Summit

Nov 04, 2021 04:05 pm ET

Prothena Reports Third Quarter 2021 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine...

Oct 28, 2021 04:05 pm ET

Prothena to Report Third Quarter 2021 Financial Results on November 4th

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its third quarter and first nine months...

Oct 01, 2021 04:30 pm ET

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 01, 2021 04:05 pm ET

Prothena Announces Executive Appointments

Sep 03, 2021 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 01, 2021 04:05 pm ET

Prothena to Participate in Upcoming September Healthcare Conferences

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in...

Aug 05, 2021 04:05 pm ET

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six...

Jul 29, 2021 04:05 pm ET

Prothena to Report Second Quarter 2021 Financial Results on August 5th

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months...

Jul 26, 2021 09:00 am ET

Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021

Jul 20, 2021 04:05 pm ET

Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021

Jul 12, 2021 09:31 am ET

Thinking about trading options or stock in Celldex Therapeutics, Tesla, Prothena Corp, Microsoft, or Annovis Bio?

NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLDX, TSLA, PRTA, MSFT, and ANVS.

Jul 12, 2021 07:00 am ET

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme

Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody...

Jun 24, 2021 08:30 am ET

Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Jun 17, 2021 09:31 am ET

Thinking about trading options or stock in Prothena Corp, CureVac, Centene Corp, AMC, or Biogen?

NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTA, CVAC, CNC, AMC, and BIIB.

Jun 16, 2021 09:31 am ET

Thinking about trading options or stock in Prothena Corp, AT&T, MicroStrategy, General Electric, or Bank of America?

NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTA, T, MSTR, GE, and BAC.

Jun 11, 2021 09:31 am ET

Thinking about trading options or stock in Crispr Therapeutics, AMC, Atomera, Prothena Corp, or Eli Lilly?

NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, AMC, ATOM, PRTA, and LLY.

Jun 10, 2021 02:18 pm ET

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

May 20, 2021 04:05 pm ET

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board...

May 11, 2021 04:05 pm ET

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2021. In...

May 10, 2021 04:05 pm ET

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

May 07, 2021 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 04, 2021 04:05 pm ET

Prothena to Report First Quarter 2021 Financial Results on May 11th

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will...

Apr 18, 2021 03:05 pm ET

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting. PRX004 showed favorable results...

Apr 15, 2021 04:05 pm ET

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

Apr 07, 2021 04:05 pm ET

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 05, 2021 04:05 pm ET

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Mar 24, 2021 08:00 am ET

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

Mar 23, 2021 04:29 pm ET

Prothena Announces Proposed Offering of Ordinary Shares

Mar 08, 2021 04:05 pm ET

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Feb 24, 2021 04:05 pm ET

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

Feb 11, 2021 08:00 am ET

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Feb 05, 2021 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 04, 2021 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th

Feb 01, 2021 04:15 pm ET

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

Prothena Corporation plc (NASDAQ:PRTA) today announced that following further analyses by the Company and multiple in-depth discussions with the U.S. Food and Drug Administration (FDA) regarding the previous analysis of patients categorized as Mayo...

Dec 09, 2020 08:00 am ET

Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

Prothena Corporation plc (NASDAQ:PRTA) today reported positive results from the Phase 1 study of PRX004, the first anti-amyloid immunotherapy designed to deplete amyloid to demonstrate efficacy in ATTR amyloidosis. In the first report of clinical...

Dec 04, 2020 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in...

Nov 04, 2020 04:05 pm ET

Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update

Nov 04, 2020 08:30 am ET

Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020

Oct 28, 2020 04:05 pm ET

Prothena to Report Third Quarter 2020 Financial Results on November 4

Oct 20, 2020 04:05 pm ET

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease

Oct 02, 2020 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in...

Sep 15, 2020 08:30 am ET

Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress

Sep 11, 2020 08:30 am ET

Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study

Prothena Corporation plc (NASDAQ:PRTA), announced that results from the Phase 2 PASADENA study of prasinezumab are being highlighted today at the International Parkinson and Movement Disorder Society's MDS Virtual Congress 2020 (MDS Congress)....

Sep 08, 2020 04:05 pm ET

Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15

Sep 03, 2020 04:05 pm ET

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders

Sep 02, 2020 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 06, 2020 04:05 pm ET

Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update

Aug 05, 2020 04:05 pm ET

Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders

Jul 30, 2020 04:05 pm ET

Prothena to Report Second Quarter 2020 Financial Results on August 6

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it...

May 27, 2020 04:05 pm ET

Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare...

May 06, 2020 04:05 pm ET

Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financial results for the first quarter of 2020. In addition, the Company provided an update on its R&D programs and...

Apr 29, 2020 04:05 pm ET

Prothena to Report First Quarter 2020 Financial Results on May 6

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after the close of the...

Apr 24, 2020 04:30 pm ET

Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19

Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020. The meeting will convene as scheduled at The Merrion Hotel, Upper Merrion...

Apr 22, 2020 09:15 am ET

Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early...

Apr 03, 2020 04:05 pm ET

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Company’s board of...

Mar 31, 2020 04:05 pm ET

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will...

Mar 03, 2020 04:05 pm ET

Prothena Announces Appointment of Brandon Smith as Chief Business Officer

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for leading Prothena’s...

Feb 12, 2020 04:05 pm ET

Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financial results for the fourth quarter and full year 2019. In addition, the Company provided 2020 financial...

Feb 05, 2020 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after...

Dec 05, 2019 04:05 pm ET

Prothena Announces Appointment of Oleg Nodelman to its Board of Directors

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in the biotechnology...

Nov 05, 2019 04:05 pm ET

Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the third quarter and first nine months of 2019. In addition, the Company provided an update on its neuroscience pipeline. “We...

Oct 29, 2019 04:05 pm ET

Prothena to Report Third Quarter 2019 Financial Results on November 5

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets. Consistent with...

Oct 07, 2019 09:00 am ET

Labaton Sucharow LLP and Levi & Korsinsky LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Ordinary Shares of Prothena Corporation plc in In re Prothena Corporation plc Securit

NEW YORK, Oct. 7, 2019 /PRNewswire/ -- Labaton Sucharow LLP and Levi & Korsinsky LLP announce that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement (NASDAQ: PRTA):

Aug 06, 2019 04:05 pm ET

Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the second quarter and first six months of 2019. In addition, the Company provided an update on its R&D programs. “We remain on...

Jul 30, 2019 04:05 pm ET

Prothena to Report Second Quarter 2019 Financial Results on August 6

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2019 on August 6, 2019 after the close of the U.S. financial markets. Consistent with...

Jul 01, 2019 04:05 pm ET

Prothena Announces Appointment of Paula K. Cobb to its Board of Directors

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of Directors. “As a biotechnology executive with wide-ranging global development, business strategy and...

May 30, 2019 04:05 pm ET

Prothena to Participate in the Jefferies Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6th at 10:30 AM ET in New York,...

May 07, 2019 04:05 pm ET

Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the first quarter of 2019. In addition, the Company provided an update on its R&D programs and 2019 financial guidance. “We...

Apr 30, 2019 04:05 pm ET

Prothena to Report First Quarter 2019 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets. Consistent with past practice, the Company...

Apr 18, 2019 04:05 pm ET

Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in newly diagnosed, treatment naïve patients with AL Amyloidosis and...

Apr 03, 2019 08:25 am ET

Analysis: Positioning to Benefit within Cleveland-Cliffs, Wix, F5 Networks, Prothena Corporation plc, McCormick & Company, and NII — Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cleveland-Cliffs Inc. (NYSE:CLF), Wix.com Ltd. (NASDAQ:WIX), F5 Networks, Inc....

Mar 14, 2019 05:15 pm ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (“Prothena” or “the Company”) (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the...

Mar 14, 2019 09:02 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Con

Mar 05, 2019 04:05 pm ET

Prothena to Participate in Upcoming March Healthcare Conferences

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the following March investor conferences: Barclays Global Healthcare...

Feb 14, 2019 04:05 pm ET

Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the fourth quarter and full year 2018. In addition, the Company provided 2019 financial guidance and an update on its R&D programs....

Feb 04, 2019 04:05 pm ET

Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14th, after the close of the U.S. financial markets....

Jan 30, 2019 08:15 am ET

Report: Developing Opportunities within Hyatt Hotels, Carter's, Globus Medical, Switch, Prothena Corporation plc, and Assurant — Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Hyatt Hotels Corporation (NYSE:H), Carter's, Inc. (NYSE:CRI), Globus...

Nov 06, 2018 04:05 pm ET

Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the third quarter and first nine months of 2018. In addition, the Company provided an update on its R&D programs. “We continue to...

Oct 30, 2018 04:05 pm ET

Prothena to Report Third Quarter 2018 Financial Results on November 6

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets. Consistent with...

Oct 16, 2018 09:10 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within 1-800 FLOWERS.COM, Bojangles', Prothena Corporation plc, Lydall, Daktronics, and ServiceSource International — New Research Emphasiz

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of 1-800 FLOWERS.COM, Inc. (NASDAQ:FLWS), Bojangles', Inc. (NASDAQ:BOJA),...

Sep 13, 2018 06:17 pm ET

The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:...

Sep 13, 2018 01:18 pm ET

September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:

Sep 06, 2018 08:21 pm ET

September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

National securities litigation law firm Glancy Prongay Murray LLP (“GPM”) reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation...

Sep 02, 2018 09:12 am ET

EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc – PRTA

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Prothena Corporation plc (NASDAQ: PRTA) from October 15, 2015 through April 20, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Prothena investors under the federal securities laws.

Aug 31, 2018 08:24 pm ET

Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

National securities litigation law firm Glancy Prongay Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Prothena Corporation plc (“Prothena” or...

Aug 28, 2018 08:15 pm ET

The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Aug 20, 2018 08:00 am ET

Investor Expectations to Drive Momentum within Rapid7, 1-800 FLOWERS.COM, SMART Global, Prothena Corporation plc, Amphastar Pharmaceuticals, and Silvercorp Metals — Discovering Underlying Factors of I

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rapid7, Inc. (NASDAQ:RPD), 1-800 FLOWERS.COM, Inc. (NASDAQ:FLWS), SMART...

Aug 09, 2018 02:39 pm ET

Notice of Voluntary Dismissal of Class Action Concerning Prothena Corporation

Levi Korsinsky, LLP announces that a notice of voluntary dismissal was filed in the securities class action entitled James v. Prothena Corporation (Case No. 3:18-cv-04261) in the USDC for the Northern District of California (“James Action”). As a...

Aug 07, 2018 04:05 pm ET

Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the second quarter and first six months of 2018. In addition, the Company provided an update on its R programs. “We are...

Aug 06, 2018 05:56 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Prothena Corporation Investors and Set a Lead Plaintiff Deadline of October 5, 2018

The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Prothena Corporation (NASDAQ: PRTA) between October 15, 2015 and April 20, 2018. You are hereby...

Jul 31, 2018 04:05 pm ET

Prothena to Report Second Quarter 2018 Financial Results on August 7

Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2018 on August 7, 2018 after the close of the U.S. financial markets. Consistent with...

Jul 24, 2018 02:52 pm ET

Investor Alert: Kaplan Fox Announces Investigation Of Prothena Corporation plc

NEW YORK, July 24, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ: PRTA). Investors who purchased Prothena common stock between October 15, 2015 and April 20, 2018 (the "Class Period") may be affected. A Class Action has been filed against Prothena and certain current and former Company executives on behalf of investors who purchased Prothena's publicly traded common stock during the Class Period.

Jul 20, 2018 09:17 pm ET

Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:

Jul 18, 2018 12:15 pm ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline - September 17, 2018

NEW YORK, July 18, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ: PRTA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Prothena securities between October 15, 2015 and April 20, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/prta.

Jul 17, 2018 03:46 pm ET

Labaton Sucharow LLP Files Securities Class Action Lawsuit on Behalf of Prothena Corporation plc Investors

Labaton Sucharow LLP (“Labaton Sucharow”) announces that on July 16, 2018, it filed a securities class action lawsuit on behalf of its client Granite Point Capital (“Granite Point”) against Prothena Corporation plc (“Prothena” or the “Company”)...

Jul 17, 2018 02:27 pm ET

Robbins Arroyo LLP: Prothena Corporation Public Limited Company (PRTA) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Prothena Corporation Public Limited Company (NasdaqGS: PRTA) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act

Jul 16, 2018 11:26 am ET

CLASS ACTION DEADLINE MONDAY for PRTA and FLR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Jul 15, 2018 12:00 am ET

SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR ATEN REPH DB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Jul 13, 2018 09:07 pm ET

The Law Offices of Howard G. Smith Reminds Investors of July 16th Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Law Offices of Howard G. Smith reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:PRTA)...

Jul 13, 2018 07:00 pm ET

CLASS ACTION DEADLINE MONDAY for PRTA and SYMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 13, 2018 12:40 pm ET

SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR DB QCOM NWL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jul 13, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Losses in Excess of $2,000,000 of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline – July 1

Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC notifies investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ:PRTA) and certain of its officers, on behalf of...

Jul 12, 2018 07:24 pm ET

July 16th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

National securities litigation law firm Glancy Prongay Murray LLP (“GPM”) reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation...

Jul 12, 2018 03:58 pm ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRTA, PPG, DB, PCG, and TAL

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Jul 11, 2018 03:27 pm ET

MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena” or ''the Company'') (NASDAQ:

Jul 11, 2018 03:08 pm ET

SHAREHOLDER ALERT – PRTA SYMC MFGP ANW ORA PCG TAL FLKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jul 11, 2018 02:15 pm ET

The Law Offices of Howard G. Smith Reminds Investors of July 16th Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Jul 11, 2018 02:01 pm ET

CLASS ACTION UPDATE for PRTA and ATEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 11, 2018 06:00 am ET

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Prothena Corporat

Jul 10, 2018 03:53 pm ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRTA, ATEN, QCOM, SBGL, and SYMC

Jul 10, 2018 02:51 pm ET

July 16th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:

Jul 10, 2018 11:19 am ET

SHAREHOLDER ALERT – KLIC PRTA SYMC PPG FLR UNM GOGO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jul 10, 2018 10:10 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Losses in Excess of $2,000,000 of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline - July 1

NEW YORK, July 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ: PRTA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Prothena securities between October 15, 2015 and April 20, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/prta.

Jul 10, 2018 09:45 am ET

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Prothena Corporation plc (PRTA)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Prothena Corporation plc (NASDAQ: PRTA) (“Prothena” or the “Company”) and other defendants, related to alleg

Jul 09, 2018 02:57 pm ET

CLASS ACTION UPDATE for KLIC, PRTA, and SYMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 06, 2018 05:34 pm ET

PRTA LOSS ALERT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc - PRTA

NEW YORK, July 6, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Prothena Corporation plc (NASDAQ: PRTA) from October 15, 2015 through April 20, 2018, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Prothena investors under the federal securities laws.

Jul 06, 2018 04:34 pm ET

DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Jul 06, 2018 10:28 am ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NWL, PRTA, PPG, DB, ANW, and REVG

Jul 05, 2018 05:56 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against Prothena Corporation plc and Certain Officers – PRTA

Pomerantz LLP announces that a class action lawsuit has been filed against Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:PRTA) and certain of its officers. The class action, filed in United States District Court, Northern...

Jul 05, 2018 04:45 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA) securities October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Prothena investors have until July 16, 2018

Jul 05, 2018 01:00 pm ET

SHAREHOLDER ALERT – PRTA MFGP ANW ORA TAL NWL FLKS HAIR GOGO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jul 05, 2018 09:02 am ET

PRTA INVESTORS REMINDER: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Prothena Corporation plc

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation has bee

Jul 03, 2018 01:00 pm ET

CLASS ACTION UPDATE for PRTA, MFGP, and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jul 02, 2018 01:11 pm ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRTA, PPG, DB, ANW, REVG and ORA

Jun 29, 2018 05:34 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm

Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:PRTA) of the July 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class...

Jun 29, 2018 04:00 pm ET

SHAREHOLDER ALERT – PRTA TAL NWL FLEX HAIR GOGO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jun 28, 2018 02:31 pm ET

CLASS ACTION UPDATE for DB, PRTA and ANW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Jun 27, 2018 12:30 pm ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INWK, ESPR, PRTA, and PPG

Jun 26, 2018 05:50 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

Jun 26, 2018 11:32 am ET

SHAREHOLDER ALERT – PRTA MFGP DB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Jun 25, 2018 04:05 pm ET

Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that Tran B. Nguyen has been appointed to the newly created...

Jun 25, 2018 12:18 pm ET

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Prothena Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 16, 2018 – PRTA

The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Prothena Corporation ("Prothena") (NASDAQ:PRTA) between October 15, 2015 and April 20, 2018. You are...

Jun 23, 2018 09:00 am ET

PRTA ALERT: Rosen Law Firm Reminds Prothena Corporation plc Investors of Important Deadline in Case– PRTA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Prothena Corporation plc (NASDAQ: PRTA) from October 15, 2015 through April 20, 2018, both dates inclusive (the “Class Period”) of the important July 16, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Prothena investors under the federal securities laws.

Jun 21, 2018 05:29 pm ET

UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PPG and PRTA

Jun 21, 2018 06:00 am ET

DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Prothena Corporation plc to Co

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Prothena Corporation plc (Nasdaq: PRTA) (“Prothena” or the “Company”) securities during the period between October 15, 2015 to April 20, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until July 16, 2018 to seek appointment as lead plaintiff.

Jun 20, 2018 09:35 am ET

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Prothena Corporation plc (PRTA)

NEW YORK, June 20, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Prothena Corporation plc (NASDAQ: PRTA) ("Prothena" or the "Company") and other defendants, related to alleged violations of federal securities laws. If you purchased Prothena stock between October 15, 2015 and April 20, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for additional information. Investors have until July 16, 2018, to move for lea

Jun 20, 2018 09:03 am ET

PRTA INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Prothena Corporation plc

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation th

Jun 19, 2018 04:05 pm ET

Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that results from the Phase 1b multiple ascending dose study of...

Jun 19, 2018 04:00 pm ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Molina Healthcare, Inc., Esperion Therapeutics, Inc., PPG Industries, Inc., Prothena Corporation, and Fl

Jun 18, 2018 07:08 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Prothena Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 16, 2018 – PRTA

Jun 15, 2018 07:00 pm ET

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Actions Involving Prothena Corporation, Fluor Corporation, PG&E Corporation

Jun 15, 2018 06:47 pm ET

PRTA LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc – PRTA

Jun 15, 2018 04:39 pm ET

UPDATE -- The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Fluor Corporation, Aceto Corporation, Prothena Corporation, Allegiant Travel Company, and Myriad

Jun 14, 2018 04:30 pm ET

The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Fluor Corporation, Aceto Corporation, Prothena Corporation, Allegiant Travel Company, and Myriad Genetics,

Jun 14, 2018 12:11 pm ET

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Prothena Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 16, 2018 – PRTA

Jun 13, 2018 04:00 pm ET

The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Prothena Corporation Shareholders and a Lead Plaintiff Deadline of July 16, 2018 (PRTA)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Prothena Corporation (NASDAQ: PRTA) who purchased shares between October 15, 2015 and April 20, 2018. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.

Jun 12, 2018 02:30 pm ET

PRTA EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Prothena Corporation and a Lead Plaintiff Deadline of July 16, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Prothena Corporation ("Prothena") (NASDAQ: PRTA) securities between October 15, 2015 and April 20, 2018.